Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Chaitanya Kurhade et al.
Summary: This study reported on the neutralizing activities of a BA.5 bivalent booster against SARS-CoV-2 Omicron sublineages. The results showed that the BA.5 bivalent booster had good neutralizing efficacy against BA.4/5 but weaker efficacy against BA.2.75.2, BQ.1.1, and XBB.1. Previous infection significantly enhanced the strength and breadth of neutralization induced by the BA.5 bivalent booster. These data support a vaccine update strategy that matches newly emerged SARS-CoV-2 variants.
Article
Biochemistry & Molecular Biology
Sophia T. Tan et al.
Summary: The study found that both vaccine-derived and naturally acquired immunity can reduce the infectiousness of individuals with Omicron variant SARS-CoV-2 infections in a prison setting. Vaccinated individuals, especially those who received booster doses and were recently vaccinated, have lower infectiousness.
Article
Immunology
Michael Asamoah-Boaheng et al.
Summary: The association between antibodies to wild-type SARS-CoV-2 antigens and the risk of breakthrough COVID-19 during the Omicron variant circulation was investigated. It was found that higher antibody levels to wild-type SARS-CoV-2 antigens after vaccination were associated with a reduced risk of COVID-19. Further research should prioritize the clinical utility of antibody levels to determine the threshold for protection and the optimal timing of boosters.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Virology
Julien Favresse et al.
Summary: Evidence on the long-term persistence of booster-mediated immunity against Omicron is crucial for pandemic management and vaccine deployment. A study found that neutralizing and binding antibodies significantly decreased after 6 months of receiving a homologous BNT162b2 booster, and this decrease was strongly correlated with vaccine efficacy against symptomatic disease. The study also highlights the need for adaptation of commercial assays to better predict neutralization in the Omicron era.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Medical Laboratory Technology
Julien Favresse et al.
Summary: This review highlights the contribution of the journal Clinical Chemistry and Laboratory Medicine (CCLM) in generating knowledge in SARS-CoV-2 diagnosis, with a special focus on COVID-19 research. It emphasizes the importance of the journal in publishing major guidelines related to COVID-19 and its dedication to helping the field better understand and diagnose this emerging disease.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Editorial Material
Immunology
Noam Barda et al.
Summary: This study reports the correlation between antibody levels and infection, finding that increasing prebooster antibody levels reduces the risk of infection.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Dan-Yu Lin et al.
Summary: In a study conducted in North Carolina, Covid-19 vaccines were found to be highly effective in preventing hospitalization and death for up to 9 months after vaccination. The decrease in protection against infection over time was attributed to both declining immunity and the emergence of the delta variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Infectious Diseases
Deborah Cromer et al.
Summary: By analyzing data on in-vitro neutralization and clinical protection, the study found that neutralizing activity against the ancestral SARS-CoV-2 is highly correlated with neutralization of variants of concern, and can still predict the vaccine's protection against these variants. Simulation results suggest that booster vaccination for previously infected individuals can provide higher levels of protection compared to primary vaccination. Although the protection may decrease within the first year after vaccination, the current vaccines can still offer robust protection in the medium term.
Letter
Medical Laboratory Technology
Julien Favresse et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Article
Virology
Ignacio Torres et al.
Summary: This study investigated whether the levels of antibodies and T cells in peripheral blood after a booster dose of the Comirnaty (R) vaccine could predict breakthrough infections caused by the Omicron variant. The results showed that these immune parameters could not reliably predict the risk of contracting COVID-19 due to the Omicron variant in nursing home residents.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Virology
Ignacio Torres et al.
Summary: This study investigated breakthrough infections of the Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in nursing home residents who were vaccinated with the Comirnaty (R) COVID-19 vaccine. The results showed that residents who had not been previously infected with SARS-CoV-2, tested negative by a lateral flow immunocromatography (LFIC) assay at 3 months after vaccination, and had lower levels of antibodies were more likely to experience vaccine breakthrough infections.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Medicine, General & Internal
Andre Ian Francis et al.
Summary: This study discusses the latest WHO-approved Covid-19 vaccine subtypes, including Pfizer, Moderna, AstraZeneca, and Janssen vaccines, along with their platforms, trials, limitations, and geographical distributions as of May 4, 2021. Multiple countries have approved the use of these vaccines.
POSTGRADUATE MEDICAL JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Ronen Arbel et al.
Summary: A retrospective analysis of data from Israel shows that a second booster shot of BNT162b2 in individuals aged 60 and over significantly reduces hospitalizations and deaths due to COVID-19.
Article
Immunology
Su Lan Yang et al.
Summary: Breakthrough infections and declining antibody titers are important factors to consider in the evaluation of vaccination policies for healthcare staff. A prospective cohort study found a significant increase in breakthrough infections among healthcare workers 10-24 weeks after receiving the BNT162b2 vaccine, coinciding with a decrease in antibody titers. Individuals with breakthrough infections had higher antibody titers post-infection compared to those without infection, particularly in symptomatic cases. The study supports the administration of booster vaccinations for healthcare staff.
EMERGING MICROBES & INFECTIONS
(2022)
Editorial Material
Medicine, General & Internal
Peter B. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ramandip Grewal et al.
Summary: This study estimated the marginal effectiveness of a fourth dose compared to a third dose of mRNA covid-19 vaccines and the vaccine effectiveness of BNT162b2 and mRNA-1273 vaccines against the omicron variant. The results showed that a fourth dose improved protection against infection, symptomatic infection, and severe outcomes. Vaccine effectiveness increased with each additional dose.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Immunology
Min Hyung Kim et al.
Summary: This study aimed to evaluate the predictive role of antibody levels in the disease progression of COVID-19 in vaccinated patients with Delta and Omicron variant infections. The results showed that increased antibody levels were associated with a decrease in the occurrence of fever, hypoxia, CRP elevation, and lymphopenia.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Biology
Constant Gillot et al.
Summary: Neutralizing antibodies are important because they can prevent virus entry into human cells. The gold standard method for detecting these antibodies is the plaque reduction neutralization test, which requires a biosafety level 3 laboratory.
Letter
Infectious Diseases
Jonathan Douxfils et al.
JOURNAL OF INFECTION
(2021)
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Barak Mizrahi et al.
Summary: The study indicates preliminary evidence of waning vaccine effectiveness of BNT162b2 among all age groups above 16, with a higher incidence of infection in those vaccinated earlier in 2021. Further investigation into long-term protection against different strains is warranted.
NATURE COMMUNICATIONS
(2021)
Article
Infectious Diseases
Julien Favresse et al.
Summary: The CRO-VAX HCP study investigated the early antibody response in healthcare professionals who received two doses of the BNT162b2 mRNA COVID-19 vaccine. Results showed that in previously infected individuals, a single dose of the vaccine may be sufficient, as they had higher antibody titres compared to uninfected individuals.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Biochemistry & Molecular Biology
Matan Levine-Tiefenbrun et al.
Summary: COVID-19 vaccines not only provide protection to individual vaccinees, but may also reduce viral load in breakthrough infections, potentially leading to lower infectiousness and further suppressing virus spread.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Kristen A. Earle et al.
Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
Article
Virology
Julien Favresse et al.
Summary: Assessing and comparing neutralizing antibodies in COVID-19 patients and vaccinated individuals revealed stronger responses in moderate-severe patients compared to mild patients, while vaccinated individuals had significantly higher NAbs levels than patients.
Article
Immunology
Julien Favresse et al.
Summary: The study aimed to assess the antibody response in healthcare professionals who had received the BNT162b2 mRNA COVID-19 vaccine, finding a decline in antibody levels at 3 months post-vaccination but maintaining a robust immune response.
EMERGING MICROBES & INFECTIONS
(2021)
Letter
Medical Laboratory Technology
Julien Favresse et al.
CLINICAL CHEMISTRY
(2020)
